ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) today announced top-line results of its pilot study for lung cancer which shows highly significant evidence of CyPath®’s ability to discriminate between cancer and non-cancer groups based on sputum samples collected in a non-invasive manner.
